title: Pegaptanib sodium for acute retinal necrosis-induced macular oedema.
authors.forename: Luis
authors.initials: L
authors.lastname: Amselem
authors.forename: Manuel
authors.initials: M
authors.lastname: Diaz-Llopis
authors.forename: Enrique
authors.initials: E
authors.lastname: Cervera
authors.forename: David
authors.initials: D
authors.lastname: Salom
authors.forename: Frederic
authors.initials: F
authors.lastname: Huste
authors.forename: Javier
authors.initials: J
authors.lastname: Montero
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D052157:Aptamers, Nucleotide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D015882:Retinal Necrosis Syndrome, Acute / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D052157:Aptamers, Nucleotide; D042461:Vascular Endothelial Growth Factor A; C495058:pegaptanib